Annovis Bio (ANVS) Projected to Post Earnings on Friday

Annovis Bio (NYSE:ANVS) is expected to be posting its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 12:00 AM ET.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Stock Performance

Shares of NYSE:ANVS opened at $2.09 on Wednesday. Annovis Bio has a 52-week low of $1.11 and a 52-week high of $7.80. The company has a market capitalization of $51.06 million, a PE ratio of -1.02 and a beta of 1.61. The company has a fifty day moving average of $2.14 and a 200-day moving average of $2.32.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANVS. Vanguard Group Inc. grew its holdings in shares of Annovis Bio by 5.9% in the third quarter. Vanguard Group Inc. now owns 738,003 shares of the company’s stock valued at $1,528,000 after acquiring an additional 41,239 shares in the last quarter. Jane Street Group LLC purchased a new position in Annovis Bio in the second quarter worth $52,000. Marshall Wace LLP purchased a new position in Annovis Bio in the second quarter worth $197,000. JPMorgan Chase & Co. grew its stake in Annovis Bio by 69.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company’s stock valued at $32,000 after purchasing an additional 6,100 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Annovis Bio by 20.1% during the 2nd quarter. Geode Capital Management LLC now owns 183,287 shares of the company’s stock valued at $398,000 after purchasing an additional 30,674 shares during the last quarter. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ANVS shares. Canaccord Genuity Group reiterated a “buy” rating and set a $17.00 price target on shares of Annovis Bio in a report on Tuesday, September 30th. HC Wainwright cut their target price on Annovis Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annovis Bio in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Annovis Bio to a “hold” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.50.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.